Embecta Corp

Embecta Corp. engages in manufacturing and distributing medical devices used in the treatment of diabetes. It delivers insulin for diabetic patients to improve their lives. The company is headquartered in Parsippany, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Embecta Corp exceeds Q1 revenue expectations and raises 2023 guidance

Embecta Corp delivered strong Q1 performance, raising financial guidance for 2023. Despite challenges in gross margins and increased OpEx spending, the company remains focused on strategic priorities and opportunities for growth.

Embecta Corp reports robust Q2 earnings, eyes growth opportunities

Embecta Corp's Q2 2023 earnings call highlighted strong financial performance, strategic priorities for 2023, and updated guidance. The company is focused on improving diabetes care, revenue diversification, and addressing challenges like the China manufacturing shutdown. Opportunities exist in partnerships, addressing needle reuse, and strategic M&A.

Embecta Corp reports Q3 revenue growth amidst margin challenges

EMBC's Q3 performance showed revenue growth and adjusted net income, despite challenges in U.S. revenue and margin decline
The company's strengths lie in successful product launches, international revenue growth, and future pipeline optimism
Challenges include revenue decline in the U.S., margin pressures, and monitoring competitive threats
Opportunities include demerger process initiation, focus on open-loop system, and improved guidance for 2023

Embecta Corp exceeds revenue expectations in Q4 2023 earnings call

Embecta Corp's Q4 2023 earnings call highlighted revenue growth, strong gross margins, and strategic priorities for fiscal 2024. Despite challenges in TSA expenses and revenue decline projections for 2024, the company remains focused on growth opportunities. Management's commitment to maintaining a 30% adjusted EBITDA margin showcases confidence in the base business.

Embecta Corp surpasses Q1 revenue expectations, raises EPS guidance

Embecta Corp's Q1 performance exceeded expectations, showcasing resilience in its core business and progress in strategic initiatives. While facing challenges related to the ERP transition, the company is well-positioned to leverage opportunities for growth and profitability.

Embecta Corp (EMBC) reports strong Q2 earnings and eyes market expansion

Embecta Corp (EMBC) delivered a robust Q2 performance, exceeding revenue expectations and raising adjusted earnings per share guidance.
The company showcased operational efficiency through successful initiatives like ERP system implementation and distribution network expansion.
While facing challenges in revenue outlook and cash flow management, Embecta remains focused on innovation and market resilience for sustained growth.

Embecta Corp reports Q3 revenue decline but affirms growth outlook

Embecta Corp's Q3 performance reflected revenue decline but strong strategic progress.
The company faces challenges in managing separation costs and addressing revenue decreases.
Opportunities lie in new product introductions, FDA applications, and market development initiatives.

Embecta Corp surpasses 2024 expectations, announces restructuring plan

Embecta Corp's Q4 2024 performance exceeded expectations with revenue growth and EBITDA margin
The company announced a restructuring plan to discontinue the insulin patch pump program for cost savings
Future strategic priorities aim to strengthen core business and expand product portfolio

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Archer-Daniels-Midland Company

Aflac

Allegion

Amgen

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Emerson Electric

Gilead Sciences

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Pfizer

Southern Company

T. Rowe Price Group

Trane Technologies plc

With the start of the final quarter of 2023, it's time to take a look back at my previous month of dividend income. Getting close to that $2,000 milestone in a month sure looks amazing. I know, those end of quarter months are always the big payers but it's still nice to see.

Dividend Income Update September 2023

American States Water

Beyond Meat

Farmers & Merchants Bancorp

iHeartMedia

SecureWorks Corp.

Seer

With the major equity indices printing some lackluster performances recently, the concept of contrarian stocks to buy might hit a bit differently now. Basically, with so many ideas printing red ink – and with analysts bashing that seemingly at every turn – a sudden reversal could yield tremendous profits.

7 Contrarian Stocks to Buy for the High-Stakes Gambler

PARSIPPANY, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Healthcare Conference in New York on Tuesday, September 12, 2023 at 2:55 p.m. ET.

embecta to Participate at the Morgan Stanley 21st Annual Healthcare Conference

Embecta Corp. (NASDAQ:EMBC ) Q3 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President of Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG Travis Steed - Bank of America Securities Operator Welcome, ladies and gentlemen, to the Fiscal Third Quarter 2023 Embecta Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay following the completion of this call.

Embecta Corp. (EMBC) Q3 2023 Earnings Call Transcript

Embecta Corp. (EMBC) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $1.07 per share a year ago.

Embecta Corp. (EMBC) Beats Q3 Earnings and Revenue Estimates

PARSIPPANY, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and nine-month periods ended June 30, 2023.

Embecta Corp. Reports Third Quarter Fiscal 2023 Financial Results

Embecta Corp.'s stock has dropped 31% since its last publication, and analysis suggests this trend may continue. Despite securing key partnerships and signing multi-year agreements, projected revenue and earnings growth is flat. Net-net, reiterate hold on Embecta Corp.

Embecta: Mammoth Effort Needed To Get Investors Over The Line, Reiterate Hold

PARSIPPANY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, will host a conference call to discuss its fiscal third quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, August 8, 2023.

embecta to Report Fiscal Third Quarter 2023 Financial Results

PARSIPPANY, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following investor conferences:

UPDATE -- embecta to Participate in Investor Conferences

Embecta Corp. (NASDAQ:EMBC ) Q2 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Sam Eiber - BTIG Travis Steed - Bank of America Securities Anthony Petrone - Mizuho Securities Operator Welcome, ladies and gentlemen to the Fiscal Second Quarter 2023 Embecta Earnings Conference Call. At this time, all participants have been placed in a listen-only mode.

Embecta Corp. (EMBC) Q2 2023 Earnings Call Transcript

PARSIPPANY, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three- and six-month periods ended March 31, 2023.

Embecta Corp. Reports Second Quarter Fiscal 2023 Financial Results

PARSIPPANY, N.J. and PALO ALTO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, and Tidepool, a 501(c)(3) nonprofit organization committed to harnessing the power of technology to provide intuitive software products that help people living with diabetes, have announced that the two organizations will partner to develop an automated insulin delivery (AID) system for people living with type 2 diabetes (T2D).

embecta and Tidepool partner to develop automated insulin delivery system for people with Type 2 diabetes

Following the company's latest numbers, there is no change to the Embecta hold thesis in my opinion. Capital productivity is weakening, evidenced by the absence of sequential growth in post-tax earnings.

Embecta: Capital Productivity, Incremental Profit Growth Key Challenges

Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.

Embecta (EMBC) to Report Q2 Earnings: What's in Store?

AbbVie

Johnson & Johnson just raised its quarterly dividend for the 61st straight year. AbbVie is counting on Skyrizi and Rinvoq and its deep pipeline to help replace lost revenue from Humira.

3 Top Dividend Kings to Buy for the Long Haul

PARSIPPANY, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal second quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 12, 2023.

embecta to Report Fiscal Second Quarter 2023 Financial Results

Southern Co 5.25 % Notes 2017-01.12.77 Global Series 2017B

The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book. Earning $1,893.81 represents 12.6% year over year increase in passive income.

DivHut Portfolio Update: March 2023

Solo Brands

HireQuest Inc

HQI, EMBC and DTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 30, 2023.

Best Momentum Stocks to Buy for March 30th

Alliance Resource Partners

Goldman Sachs BDC

HQI, EMBC, DTC, GSBD and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on March 30, 2023.

New Strong Buy Stocks for March 30th

Innovage Holding Corp

OncoCyte

The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most.

3 Medical Services Stocks to Buy Amid Industry Challenges

Piedmont Lithium

Textron

PLL, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 24, 2023.

Best Momentum Stocks to Buy for February 24th

Deere & Company

LCNB

PLL, TXT, EMBC, DE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on February 24, 2023.

New Strong Buy Stocks for February 24th

Deutsche Telekom AG

DTEGY, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2023.

Best Value Stocks to Buy for February 24th

Highlights the critical role people with diabetes play in their own care and treatment Highlights the critical role people with diabetes play in their own care and treatment

embecta sponsors educational symposium at ATTD 2023

Twin beats and raised guidance make for a good day on the market for the diabetes care specialist.

News for Embecta Corp Stock (EMBC)